Prime Medicine (PRME) Profit After Tax (2021 - 2026)
Prime Medicine (PRME) posted Profit After Tax of -$49.2 million for Q1 2026, down 6.97% on a QoQ basis from -$46.0 million in Q4 2025, and up 5.2% year-over-year from -$46.8 million in Q1 2025.
Prime Medicine (PRME) Profit After Tax (2021 - 2026) Analysis & Trends
Prime Medicine's Profit After Tax history runs 6 years deep, the most recent figure standing at -$49.2 million for Q1 2026.
- Quarterly Profit After Tax rose 5.2% year-over-year to -$49.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.4 million (up 1.81% YoY) and the FY2025 annual result came in at -$201.1 million, down 2.64% from the prior year.
- Profit After Tax was -$49.2 million for Q1 2026 at Prime Medicine, down from -$46.0 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$23.8 million in Q1 2022 and bottomed at -$65.5 million in Q4 2023.
- A 5-year average of -$46.2 million and a median of -$49.2 million in 2026 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 78.83% — and 2024, when it soared 35.47%.
- Prime Medicine's Profit After Tax stood at -$59.5 million in 2022, then decreased by 10.14% to -$65.5 million in 2023, then soared by 35.47% to -$42.3 million in 2024, then dropped by 8.8% to -$46.0 million in 2025, then dropped by 6.97% to -$49.2 million in 2026.
- Business Quant data shows PRME's Profit After Tax at -$49.2 million in Q1 2026, -$46.0 million in Q4 2025, and -$50.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Prime Medicine | 524.20 Mn | 524.20 Mn | - | -49.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.21 Mn |
| Dec 31, 2025 | -46.00 Mn |
| Sep 30, 2025 | -50.58 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.91 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.51 Mn |
| Sep 30, 2023 | -50.59 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -59.48 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -29.35 Mn |
| Mar 31, 2022 | -23.84 Mn |
| Dec 31, 2021 | -50.55 Mn |
| Sep 30, 2021 | -16.41 Mn |